Brustkrebszentrum Paderborn is pioneering precision oncology in Germany, offering patients access to cutting-edge therapies—including PARP inhibitors and novel antibody-drug conjugates—directly through clinical trials. As of this week, the center reports that 68% of eligible patients in its Phase II study for metastatic triple-negative breast cancer (TNBC) achieved disease stabilization or partial remission, exceeding the 50% benchmark set by the European Society for Medical Oncology (ESMO) for experimental therapies. Funding comes from a €12 million public-private partnership with the German Cancer Aid (Deutsche Krebshilfe) and Pfizer Oncology.
The center’s approach bridges a critical gap in European cancer care: while the U.S. FDA approved sacituzumab govitecan (Trodelvy) for TNBC in 2021, the European Medicines Agency (EMA) delayed its approval until 2025 due to concerns over hematologic toxicity. Paderborn’s real-world data—collected from 127 patients since 2023—shows that combining Trodelvy with olaparib (Lynparza), a PARP inhibitor, reduced severe neutropenia (grade 3/4) from 42% (historical control) to 23%, according to Dr. Michael P. Lux, the center’s director.
In Plain English: The Clinical Takeaway
- What’s new? Paderborn is testing a drug combo (Trodelvy + Lynparza) that shrinks or stops TNBC tumors in 68% of cases—higher than standard chemo.
- Why does it matter? The EMA’s delay means European patients often miss out on U.S.-approved drugs. Paderborn’s trial lets them access it early.
- Watch for: Severe side effects like low white blood cell counts (neutropenia) occur in 1 in 4 patients, but the combo cuts that risk nearly in half.
How Paderborn’s Trial Compares to Global Standards
Triple-negative breast cancer (TNBC) accounts for 15% of all breast cancers globally, with a 5-year survival rate of just 22% in metastatic cases [source: The Lancet Oncology, 2022]. Paderborn’s Phase II trial—published this week in Annals of Oncology—enrolls patients who’ve failed prior chemotherapy, a population with historically poor outcomes. The center’s median progression-free survival (PFS) of 7.3 months (vs. 4.8 months for standard chemo) aligns with U.S. data but exceeds European benchmarks, where access to Trodelvy remains restricted.
Key difference: While the U.S. FDA approved Trodelvy based on a 30.2% objective response rate (ORR) in its pivotal ASCENT trial (N Engl J Med, 2021), Paderborn’s combo therapy achieves a 28.3% ORR—comparable but with fewer blood-related side effects. “The olaparib addition may mitigate DNA damage repair pathway exhaustion, a known limitation of Trodelvy monotherapy,” explains Dr. Anna Varga, a molecular oncologist at the University of Heidelberg and lead investigator on the EORTC’s TNBC biomarker study.
“The olaparib-Trodelvy combination represents a paradigm shift for TNBC patients who’ve exhausted standard options. What’s striking is the reduction in neutropenia—a side effect that historically sidelined 40% of patients. This isn’t just incremental progress; it’s a redefinition of tolerability.”
Why Europe’s Drug Approval Lag Puts Patients at Risk
The EMA’s 2025 approval of Trodelvy—nearly four years after the FDA’s green light—highlights a systemic delay in European oncology. Paderborn’s trial exemplifies how compassionate use programs (allowing pre-approval access to experimental drugs) can mitigate this gap. According to the EMA’s 2025 press release, 38% of EU patients with TNBC still lack access to targeted therapies due to regulatory backlogs. Paderborn’s model—partnering with Deutsche Krebshilfe and Pfizer—accelerates patient enrollment by waiving some trial costs for low-income participants.
Regional impact: Germany’s Onkologische Spitzenzentren (Cancer Centers of Excellence) now include Paderborn as a reference site for TNBC trials, potentially reducing the 6-month wait time for experimental therapies in other German states. “This trial is a template for how public-private partnerships can bypass bureaucratic hurdles,” says Dr. Lux. “But the real test will be whether other centers adopt the olaparib-Trodelvy protocol once the EMA finalizes its approval.”
| Metric | Paderborn Trial (2023–2026) | U.S. ASCENT Trial (2019–2021) | Standard Chemo (CapeCitabine) |
|---|---|---|---|
| Objective Response Rate (ORR) | 28.3% | 30.2% | 13.8% |
| Grade 3/4 Neutropenia | 23% | 42% | 35% |
| Median PFS (months) | 7.3 | 5.6 | 4.2 |
| Patient Enrollment (N) | 127 | 408 | N/A (historical data) |
Mechanism of Action: Why This Combo Works
Trodelvy (sacituzumab govitecan) is an antibody-drug conjugate (ADC) that delivers SN-38—a topoisomerase I inhibitor—to cancer cells via a trojan-horse mechanism. Olaparib, a PARP inhibitor, blocks DNA repair in BRCA-mutated or homologous recombination-deficient (HRD) tumors. Together, they create a “double hit”: Trodelvy induces DNA damage, while olaparib prevents cells from fixing it. “The synergy isn’t just additive; it’s synergistic,” notes Dr. Lux. “We’re seeing responses in patients whose tumors were previously resistant to PARP inhibitors alone.”
Epidemiological context: 45% of TNBC cases in Europe carry BRCA mutations or HRD signatures [source: Nature Reviews Cancer, 2021], making them prime candidates for this combo. Paderborn’s trial includes 56 BRCA-mutated patients, of whom 39% achieved partial remission—a rate double that of olaparib monotherapy in prior studies.
Contraindications & When to Consult a Doctor
This therapy is not suitable for patients with:
- Severe liver impairment (Child-Pugh Class B/C) due to Trodelvy’s hepatic metabolism.
- Active infections (olaparib suppresses immune surveillance).
- Pregnancy or breastfeeding (both drugs are teratogenic).
- Prior exposure to >6 cycles of anthracyclines (increases cardiotoxicity risk).
Seek emergency care if you experience:
- Fever >38.5°C with chills (sign of neutropenic sepsis).
- Severe diarrhea (>7 episodes/day) or abdominal pain (Trodelvy-induced colitis).
- Sudden confusion or vision changes (olaparib-related cerebellar toxicity).
“Patients on this combo require weekly blood monitoring for the first 3 months,” warns Dr. Lux. “But the trade-off—fewer infections and better quality of life—is worth it for those with aggressive TNBC.”
What Happens Next: Regulatory and Clinical Trajectories
The EMA’s final decision on Trodelvy’s approval is expected by December 2026. If approved, Paderborn’s data could accelerate reimbursement negotiations with German health insurers, who currently cover olaparib but not Trodelvy. Meanwhile, the center is expanding its trial to include PD-L1-positive TNBC patients, a subgroup with unmet needs. “We’re also exploring whether adding immune checkpoint inhibitors like atezolizumab can further boost responses,” says Dr. Lux.
Global watch: The WHO’s 2025 Global Breast Cancer Initiative highlights TNBC as a priority, with a goal to increase 5-year survival rates to 40% by 2030. Paderborn’s model—combining compassionate use with rigorous real-world data—could serve as a blueprint for other European centers facing similar delays.
References
- The Lancet Oncology (2022): “Global burden of triple-negative breast cancer.”
- EMA (2025): “Sacituzumab govitecan approval for metastatic TNBC.”
- Nature Reviews Cancer (2021): “BRCA mutations in TNBC: prevalence and therapeutic implications.”
- NEJM (2021): “ASCENT trial results for sacituzumab govitecan.”
- Annals of Oncology (2026): “Olaparib-Trodelvy combo in metastatic TNBC: Paderborn Phase II data.”
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult your healthcare provider before making treatment decisions.
